Abstract 5754: Targeting miR-92b with peptide-modified liposomes for glioblastoma treatment

Abstract Focusing on enhancing drug delivery to the brain, we aim to optimize a nanocarrier system with a specific focus on glioblastoma (GBM). This involves the utilization of spherical nucleic acids (SNAs) enclosed in peptide-modified liposomes, a configuration previously proven to effectively penetrate the blood-brain barrier (BBB) in a GBM mouse model. Our objective is to enhance the nanocarrier's treatment load by optimizing the attachment of oligonucleotide-modified gold nanoparticles (OMI) to the SNAs. MicroRNAs (miRNAs) play crucial roles in GBM pathogenesis, with miR-92b identified as overexpressed in various cancers, including GBM. Previous research from our lab implicated miR-92b in targeting proteins (FBXW7 Part 1 (Regular Abstracts) ; 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84 (6Suppl): Abstract nr 5754.